Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M. 

A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells. 

Cancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.

Ysios Capital, a biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal.

A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology. 

CYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.

Integrating the disparate stages of drug development is the most time and cost-efficient way of turning a promising candidate compound into a pharmaceutical product. A CDMO that offers coordinated end-to-end services simplifies oversight.

The CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.

European stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies – this time also including companies from Germany, Italy, Spain, and Switzerland.

Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China.